A phase IIa, open label, single centre study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of orally dosed MBF-015 in Huntington's disease patients
MBF-015CT-02 · Medibiofarma S.L.
Phase 2 study testing MBF-015 in Huntington's disease.
Temporarily haltedPhase 2Not specifiedCTIS (EU)Treatment trial
- EU sites are temporarily halted (CTIS (EU))
Recruiting in: SpainExact site not listed by the study registry.
Preparing a short plain-English summary.
